# A Real-world Study of Inetetamab for First-line Treatment of MBC

> **NCT05980208** · — · NOT_YET_RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Breast Cancer
- Real-world Study

## Interventions

- **DRUG:** Inetetamab

## Key facts

- **NCT ID:** NCT05980208
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05980208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05980208, "A Real-world Study of Inetetamab for First-line Treatment of MBC". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05980208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*